Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc. (COLL)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Year ended December 31, 2024
Business Overview: Collegium is a biopharmaceutical company focused on treating moderate to severe pain and Attention Deficit Hyperactivity Disorder (ADHD). Its portfolio includes Jornay PM (ADHD), Belbuca, Xtampza ER, Nucynta ER/IR (pain), and Symproic (opioid-induced constipation).
Key Event: On September 3, 2024, the Company completed the acquisition of Ironshore Therapeutics, Inc., adding Jornay PM to its portfolio and expanding its commercial presence into the ADHD market.
Key Financial Metrics
| Metric (in millions) | 2024 | 2023 |
|---|---|---|
| Net Product Revenues | $631.4 | $566.8 |
| Gross Profit | $377.3 | $326.2 |
| Net Income | $69.2 | $48.2 |
| Diluted EPS | $1.86 | $1.29 |
| Adjusted EBITDA | $401.2 | $367.0 |
| Operating Cash Flow | $205.0 | $274.7 |
| Cash & Cash Equivalents (Year End) | $70.6 | $238.9 |
| Total Debt (Principal) | $871.2 | $424.8 |
Note: Total Debt includes $629.7M in 2024 Term Loan principal and $241.5M in 2029 Convertible Notes principal.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased by $64.6 million (11.4%) driven primarily by the inclusion of Jornay PM revenue ($37.2M) following the Ironshore acquisition, alongside growth in Belbuca ($29.2M) and Xtampza ER ($14.0M). This was partially offset by declines in Nucynta Products ($14.3M) and Symproic ($1.4M).
- Cost Structure: Cost of product revenues (excluding amortization) decreased by $6.0 million due to the absence of inventory step-up basis costs from the 2022 BDSI acquisition. However, intangible asset amortization increased by $19.5 million to $165.3 million, primarily due to the Ironshore acquisition.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses rose by $51.2 million to $210.4 million. Increases were driven by $24.3 million in acquisition-related expenses, $23.1 million in higher salaries/benefits (including the new Jornay sales force and CEO transition costs), and $9.5 million in sales and marketing expenses.
- Debt Profile: The Company refinanced its 2022 Term Loan with a new $645.8 million 2024 Term Loan in July 2024 to fund the Ironshore acquisition. The 2026 Convertible Notes were fully redeemed in June 2024, resulting in a $7.2 million loss on extinguishment.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- The Company expects to expand its ADHD sales force from approximately 150 to 180 representatives in the first half of 2025.
- Management believes current cash, cash equivalents, and marketable securities, combined with operating cash flows, are sufficient to fund operations and debt service for the foreseeable future.
- A share repurchase program of up to $150.0 million was authorized in January 2024; as of December 31, 2024, $90.0 million remained available.
Key Risks & Contingencies:
- Debt Obligations: The Company carries substantial indebtedness ($629.7M Term Loan + $241.5M Convertible Notes). The Term Loan bears a variable interest rate (SOFR + 4.50% + spread adjustment) and requires quarterly amortization. Failure to comply with covenants could trigger default.
- Regulatory & Litigation: Ongoing patent litigation with Purdue regarding Xtampza ER and Nucynta Products. The Company is also subject to opioid-related investigations and litigation, though a Master Settlement Agreement resolved 27 pending lawsuits in 2022.
- Supply Chain: Reliance on sole or limited suppliers for active pharmaceutical ingredients (APIs), particularly for controlled substances (Schedule II and III), creates supply risk. The ADHD market has recently faced supply chain interruptions due to DEA quota limitations.
- Generic Competition: Risk of generic entry for Belbuca and Nucynta Products, though pediatric exclusivity for Nucynta IR has been extended to July 2026.
Investor Verification Checklist
- Debt Covenants: Verify compliance with financial covenants in the 2024 Term Loan and 2029 Convertible Notes indentures, specifically regarding leverage and interest coverage ratios.
- Jornay Integration: Assess the actual revenue contribution and sales force expansion progress of Jornay PM in Q1 2025 compared to the Q4 2024 ramp-up.
- Patent Litigation Status: Monitor developments in the Purdue litigation regarding Xtampza ER and Nucynta, as adverse outcomes could impact future revenue streams.
- API Supply Quotas: Confirm that DEA production quotas for methylphenidate (Jornay) and oxycodone (Xtampza) are sufficient to meet projected demand without supply interruptions.
- Share Repurchases: Track the utilization of the remaining $90 million repurchase authorization and its impact on diluted share count.